Imaging News and Research

RSS

Projects investigating placebo effects in Parkinson's disease receive funds

The Michael J. Fox Foundation for Parkinson's Research announced funding for two projects investigating the placebo effect in Parkinson's disease.

30 Dec 2009

Luna Innovations acquires intellectual property assets of Tego Biosciences

Luna Innovations Incorporated has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.

29 Dec 2009

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

29 Dec 2009

Tego Biosciences sells intellectual property portfolio to Luna Innovations

Arrowhead Research Corporation today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property (IP) to Luna Innovations, Inc., a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines

29 Dec 2009

Grant of $2 million awarded to understand PIGD in Parkinson's disease

The Michael J. Fox Foundation for Parkinson's Research has awarded a total of $2 million to five research teams carrying out clinical studies to refine understanding of postural instability and gait disturbances (PIGD) in Parkinson's disease, and help speed the development of urgently needed treatments.

29 Dec 2009

Community Health Systems' subsidiary enters into affiliation agreement with Rockwood Clinic

Community Health Systems, Inc. announced today that a subsidiary has entered into an affiliation agreement with Rockwood Clinic, P.S., a multi-specialty clinic with 32 locations across the Inland Northwest region of the State of Washington.

28 Dec 2009

HealthEast and Controlled Affiliates' hospital facility revenue bonds affirmed 'BBB-'

Fitch Ratings has affirmed the unenhanced 'BBB-' long-term rating on HealthEast and Controlled Affiliates' hospital facility revenue bonds as part of its continuous surveillance effort.

24 Dec 2009

Planet Green to be acquired by IMAGIN Molecular

IMAGIN Molecular Corporation (OTCBB: IMGM) has agreed in a letter of intent to issue 49% of the post capitalization of IMGM in exchange for 84,000,000 Positron Corporation common shares plus 100% of the equity of the Planet Green Bottle, all IMGM shares to be distributed to shareholders or affiliates of Planet Green.

24 Dec 2009

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention (PCI), a procedure that treats narrowed blood vessels.

23 Dec 2009

SNM urges Congress to implement long-term solution for medical reimbursement rates

SNM is pleased that the U.S. Congress has passed a fix to freeze the conversion factor at the 2009 rate for physicians, which will ensure that millions of patients continue to receive medical coverage for critical diagnostic imaging tests and therapeutics.

23 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Findings may lead to new methods for diagnosing osteoporosis

Using a technique that provides detailed images of nanoscale structures, researchers at the University of Michigan and Detroit's Henry Ford Hospital have discovered changes in the collagen component of bone that directly relate to bone health.

23 Dec 2009

Study reveals patient characteristics can affect image quality of MDCT scans

A large multicenter international trial found that the image quality of multi-detector computed tomography (MDCT) scans, used for the noninvasive detection of coronary artery disease, can be significantly affected by patient characteristics such as ethnicity, body mass index (BMI), and heart rate, according to a study in the January issue of the American Journal of Roentgenology.

23 Dec 2009

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

Researchers at Children's Hospital Boston and Brigham and Women's Hospital have received funding from the National Heart, Lung, and Blood Institute (NHLBI) to support their search for undiscovered gene defects that cause congenital heart disease. The $4.19 million, 6-year grant is part of the Pediatric Cardiac Genomics Consortium (PCGC), which seeks to identify genetic and epigenetic causes of human congenital heart disease, and relate genetic variants present in the congenital heart disease patient population to clinical outcomes.

23 Dec 2009

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

On the morning of December 17, 2009, UPMC physicians used Gamma Knife® surgery to treat the center's 10,000th patient, an 81-year-old male with a tumor deep in his brainstem, a site where traditional surgery would have been impossible. Gamma Knife surgery is performed using Elekta's Leksell Gamma Knife system, which directs up to 201 pencil-thin beams of therapeutic radiation precisely on brain tumors and other targets in the head.

From Elekta 23 Dec 2009

CT can be a preferred technique for diagnosing PE, according to study

Computed tomography (CT), a highly accurate, readily available medical imaging technique, is the overwhelmingly preferred technique of emergency physicians and radiologists for the diagnosis of pulmonary embolism (PE), according to a study in the January issue of the American Journal of Roentgenology.

23 Dec 2009

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

AdMeTech Foundation, a nonprofit organization, announced today that the U.S. Congress has approved $1.6 million for funding of its groundbreaking research program aimed at developing novel imaging technologies for early prostate cancer detection, which in turn is critical for saving lives and designing customized patient care, including the most effective and the least invasive approach.

23 Dec 2009

Elizabethtown DI exceeds standard performance markers set by the RBMA

Opening day for any business is generally a nerve-wracking experience. Last-minute surprises are not uncommon. For Shonna Galloway, administrator for the brand-new Elizabethtown Diagnostic Imaging, however, the day before her employer's grand opening in October 2007 was one she'll never forget.

23 Dec 2009

Pancreas 3-D imaging useful in preoperative assessment of pancreatic carcinoma patients

In the field of hepatic imaging in the context of living liver donors and before complex partial liver resections, three-dimensional imaging of the liver, hepatic vessels and bile ducts has managed to become established in some centers. In this case, in addition to visualization, the volumetry of various liver sections is of interest. Moreover, the three-dimensional reconstruction can be used preoperatively to consider various resection options and to evaluate their technical feasibility with regard to vascular and bile duct anatomy and to the expected liver volume after surgery.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

Imaging News and Research

Projects investigating placebo effects in Parkinson's disease receive funds

Luna Innovations acquires intellectual property assets of Tego Biosciences

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

Tego Biosciences sells intellectual property portfolio to Luna Innovations

Grant of $2 million awarded to understand PIGD in Parkinson's disease

Community Health Systems' subsidiary enters into affiliation agreement with Rockwood Clinic

HealthEast and Controlled Affiliates' hospital facility revenue bonds affirmed 'BBB-'

Planet Green to be acquired by IMAGIN Molecular

Volcano lauds revised guidelines for treating severe coronary artery disease patients

SNM urges Congress to implement long-term solution for medical reimbursement rates

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Findings may lead to new methods for diagnosing osteoporosis

Study reveals patient characteristics can affect image quality of MDCT scans

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

CT can be a preferred technique for diagnosing PE, according to study

U.S. Congress approves $1.6 million for AdMeTech Foundation's research program

Elizabethtown DI exceeds standard performance markers set by the RBMA

Pancreas 3-D imaging useful in preoperative assessment of pancreatic carcinoma patients

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News